Brief: Horizon Therapeutics Says Additional Data From Phase 4 Tepezza Clinical Trial Presented At The Endocrine Society Annual Meeting

Horizon Therapeutics

17/06/2023 22:01

June 17 (Reuters) - Horizon Therapeutics PLC  HZNP.O :
    * ADDITIONAL DATA FROM PHASE 4 TEPEZZA® (TEPROTUMUMAB-TRBW)
CLINICAL TRIAL PRESENTED AT THE ENDOCRINE SOCIETY ANNUAL MEETING
REINFORCES EFFICACY IN PEOPLE WITH THYROID EYE DISEASE (TED)
REGARDLESS OF DISEASE ACTIVITY OR DURATION
    * HORIZON  - DATA AT WEEK 24 SHOW 2.41 MM REDUCTION IN
PROPTOSIS
IN PATIENTS TREATED WITH TEPEZZA COMPARED WITH 0.92 MM IN THOSE
WHO RECEIVED PLACEBO
    * HORIZON THERAPEUTICS - 62% OF TEPEZZA PATIENTS HAD
CLINICALLY
MEANINGFUL IMPROVEMENT IN PROPTOSIS (≥2 MM) COMPARED WITH 25% OF
PLACEBO PATIENTS

Source text for Eikon:  ID:nBw5B35ZJa 
Further company coverage:  HZNP.O 

 ((Reuters.Briefs@thomsonreuters.com;))